Second U.S. Suit Against Takeda Actos Opens In Baltimore Court
This article was originally published in PharmAsia News
Executive Summary
A second trial against Takeda Pharmaceutical and its $4.5 billion diabetes drug Actos (pioglitazone) has started in the U.S., this one in the state of Maryland.